Literature DB >> 6703685

Mezlocillin pharmacokinetics in pediatric oncology patients.

W G Kramer, L K Pickering, S Culbert, L S Frankel.   

Abstract

The pharmacokinetics of mezlocillin were studied in 31 children (age, 2 to 19 years) with malignancies and normal renal and hepatic functions. Mezlocillin was administered intravenously over 30 min every 4 h at doses ranging from 12.2 to 125 mg/kg. Blood samples were obtained over one dosage interval at steady state. For all patients, the mean clearance was 0.21 +/- 0.11 liter/h per kg, the mean distribution volume was 0.26 +/- 0.13 liter/kg, and the mean elimination half-life was 0.97 +/- 0.51 h. Trough concentrations were 23.0 +/- 29.9 mg/liter before the dose was administered and 20.4 +/- 27.5 mg/liter at the end of the dosing interval. Peak concentrations averaged 245 +/- 90.4 mg/liter, and average concentrations for the dosing interval were 83.7 +/- 40.4 mg/liter. There were no apparent effects of sex, malignancy, age, or dose on either the kinetic parameters or plasma concentrations. Overall, the disposition parameters for mezlocillin in this patient group were comparable to those reported in adults.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6703685      PMCID: PMC185436          DOI: 10.1128/AAC.25.1.62

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Kinetics of intravenous mezlocillin in chronic hemodialysis patients.

Authors:  E Francke; S Mehta; H C Neu; G B Appel
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

2.  Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth.

Authors:  B Friis-Hansen
Journal:  Pediatrics       Date:  1971-01       Impact factor: 7.124

3.  Pharmacokinetic studies of mezlocillin in newborn infants.

Authors:  T Rubio; F Wirth; E Karotkin
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

4.  Clinical pharmacology and efficacy of mezlocillin in paediatric patients with malignancy.

Authors:  L K Pickering; W G Kramer; D A Armes; L S Frankel; I R Townsend; S Culbert
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

5.  Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.

Authors:  D Kampf; R Schurig; K Weihermüller; D Förster
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

6.  Mezlocillin pharmacokinetics in renal impairment.

Authors:  G R Aronoff; R S Sloan; F C Luft; R L Nelson; D R Maxwell; S A Kleit
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

7.  Pharmacokinetics of mezlocillin in healthy volunteers.

Authors:  T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.

Authors:  N Frimodt-Möller; S Maigaard; R D Toothaker; R W Bundtzen; M V Brodey; W A Craig; P G Welling; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  Mezlocillin pharmacokinetics in patients with normal and impaired renal functions.

Authors:  T Bergan; E K Brodwall; E Wiik-Larsen
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

10.  Mezlocillin in infants and children: efficacy, safety and pharmacokinetics.

Authors:  H Trujillo; A Bustos-González; L C Peláez; D Halpert; G Mejía; C T Zapata; B Taboada
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

  10 in total
  3 in total

Review 1.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Pharmacokinetics of anti-infective agents in paediatric patients.

Authors:  D R Butler; R J Kuhn; M H Chandler
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

3.  Improved micromethod for mezlocillin quantitation in serum and urine by high-pressure liquid chromatography.

Authors:  D Fiore; F A Auger; G L Drusano; V R Dandu; L J Lesko
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.